survival analysis of intrahepatic arterial infusion of endostar combined with transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma
Clicks: 160
ID: 178278
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
160 views
18 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #58 of 78 articles by views in lontar komputer
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
ObjectiveTo assess the efficacy of intrahepatic arterial infusion of Endostar (rh-endostatin, YH-16) combined with transcatheter arterial chemoembolization (TACE) for the treatment of advanced hepatocellular carcinoma (aHCC). MethodsThe study enrolled 76 aHCC patients who were admitted to and treated at the Petroleum Hospital Affiliated to Tianjin Medical University during September 2009 to June 2011. Of these, 44 patients were treated with TACE plus Endostar, and the other 32 (the control group) with TACE alone. After treatment, all patients were subjected to non-scheduled re-examination by computed tomography (or magnetic resonance imaging), in order to check tumor recurrence (or metastasis) and angiogenesis. Count data were compared between groups using the χ2 test. Survival curves were plotted using the Kaplan-Meier method, and postoperative survival differences were analyzed using the log-rank test. ResultsCompared with the control group, the experimental group treated with TACE plus Endostar had significantly increased response rate (7045% vs. 43.75%, χ2=5.47, P＜0.05) and disease control rate (84.09% vs. 56.25%, χ2=7.18, P＜0.01). The median progression-free survival significantly differed between groups (9.00 vs. 5.00 months , P=0.044), whereas the median overall survival showed no significant difference (10.64 vs. 8.11 months, P=0.448). ConclusionTACE plus Endostar significantly improves the short-term outcome and progression-free survival but has little effect on the overall survival span in patients with aHCC.
| Reference Key |
qi2015linchuangsurvival
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;LIU Qi |
| Journal | lontar komputer |
| Year | 2015 |
| DOI |
10.3969/j.issn.1001-5256.2015.02.019
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.